Flatiron Health is a healthtech company expanding the possibilities for point-of-care solutions in oncology and using data for good to power smarter care for every person with cancer. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health recently launched new global prostate cancer datasets. This launch covers the US, UK, and Germany. Furthermore, these datasets provide vital real-world evidence. Consequently, they set a new standard in oncology research globally.
Globally, prostate cancer impacts nearly 1.5 million patients yearly. However, studying real-world evidence across borders remains incredibly difficult. Therefore, Flatiron built the prostate cancer Panoramic datasets. These datasets include records of almost 400,000 patients.
Moreover, Flatiron leverages proprietary AI and large language models. They deliver structured and unstructured EHR data globally. Thus, researchers can analyze patient outcomes seamlessly. This unprecedented interoperability improves global evidence strategies significantly.
“Flatiron is not just adding more data; we are building the singular destination for global oncology intelligence,” said Kate Estep, Chief Product Officer at Flatiron Health. “By unifying fragmented global records into a single evidence platform, we are fundamentally changing how our customers develop therapies and—most importantly—when patients can access them.”
Advancing AI Healthtech and Oncology
The datasets provide vital PSMA PET scan data. Also, they include PSA values and 19 HRR genes. Therefore, researchers can track recurrence and progression details. This helps identify patients benefiting most from novel therapies.
Furthermore, AI captures newly approved treatments very quickly. Local expert teams validate all data thoroughly. Consequently, Flatiron meets rigorous quality standards globally.
“The field of prostate cancer is evolving at a rapid pace, changing how care is sequenced from early-stage disease through metastatic CRPC and improving outcomes for patients. Yet critical evidence gaps remain, as we see significant regional variation in how novel therapies are used, and in how uneven access to advanced diagnostics differentially influences treatment decisions,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “From a clinical perspective, Flatiron’s global Panoramic datasets directly address these evidence gaps, enabling life science companies to increase confidence in decision-making earlier and accelerate development timelines across diseases and geographies, thereby bringing the next generation of precision medicine to all patients sooner.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
